Marc J. Fishman, M.D.

Marc J. Fishman, M.D.
Marc J. Fishman, M.D.
Affiliated Senior Research Scientist

M.D., Columbia College of Physicians and Surgeons
mjfishman@comcast.net
Phone: 410-233-1400
Research Interests

Dr. Fishman is board certified in addiction psychiatry and addiction medicine. He is a member of the Psychiatry faculty of the Johns Hopkins University School of Medicine, and Medical Director of Maryland Treatment Centers.

Dr Fishman leads Maryland Treatment Centers, a regional behavioral health care provider, which includes Mountain Manor Treatment Center in Baltimore for adolescents, Mountain Manor Treatment Center in Emmitsburg MD for adults, as well as several other inpatient and outpatient programs. In that role he has been involved in development and implementation of innovative programming in addiction and co-occurring disorder treatment. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and addiction with co-morbid pain. His research work has focused on models of care and treatment outcomes in adolescent addictions, in particular opioid dependence.

Dr. Fishman served as a co-editor for the most recent edition of ASAM’s Patient Placement Criteria (PPC 2-R), and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Treatment Criteria Committee for ASAM. He is the President (2010-12) of the Maryland Society of Addiction Medicine.

Selected Publications
Gordon, M.S., Blue, T., Vocci, F., Mitchell, S., Wenzel, K., & Fishman, M. (2024). Buprenorphine dose induction in opioid non-tolerant individuals in jail. Drug and Alcohol Dependence Reports, 12 (September),100261.
Monico, L. B., Fletcher, J. B., Ross, T., Schwartz, R. P., Fishman, M. J., Gryczynski, J., & Mitchell, S. G. (2024). Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder. Journal of substance use and addiction treatment, 162, 209334. https://doi.org/10.1016/j.josat.2024.209334.
Hogue, A., Satcher, M. F., Drazdowski, T. K., Hagaman, A., Hibbard, P. F., Sheidow, A. J., Coetzer-Liversagef, A., Mitchell, S. G., Watson, D. P., Wilson, K. J., Muench, F., Fishman, M., Wenzel, K., de Martell, S. C., & Stein, L. A. R. (2023). Linkage facilitation services for opioid use disorder: Taxonomy of facilitation practitioners, goals, and activities. J Subst Use Addict Treat, 209217. https://doi.org/10.1016/j.josat.2023.209217.
Mitchell, S. G., Fletcher, J. B., Monico, L. B., Gryczynski, J., Fishman, M. J., O’Grady, K. E., & Schwartz, R. P. (2023). Comparing outcomes of extended-release naltrexone in adolescents and young adults with opioid use disorder. J Subst Use Addict Treat, 209162. https://doi.org/10.1016/j.josat.2023.209162.
Orme, S., Zarkin, G. A., Dunlap, L. J., Monico, L. B., Gryczynski, J., Fishman, M. J., Schwartz, R. P., O’Grady, K. E., & Mitchell, S. G. (2023). Health care use and cost of treatment for adolescents and young adults with opioid use disorder. J Subst Use Addict Treat, 154, 209137. https://doi.org/10.1016/j.josat.2023.209137.
Monico, L. B., Ludwig, A., Lertch, E., Schwartz, R. P., Fishman, M., & Mitchell, S. G. (2022). Post-residential treatment outpatient care preferences: Perspectives of youth with opioid use disorder. Journal of Substance Abuse Treatment, 137 , 108692.Doi: 10.1016/j.jsat.2021.108692.
Gordon, M. S., Mitchell, S. G., Blue, T. R., Vocci, F. J., Fishman, M. J., Murphy, S. M., Couvillion, K., Maher, K., Ryan, D., Wenzel, K., Danner, M. L., & Jarvis, D. K. (2021). A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. Journal of Substance Abuse Treatment, 128, 108241. https://doi.org/10.1016/j.jsat.2020.108241.
Ludwig, A., Monico, L. B., Gryczynski, J., Lertch, E., Schwartz, R. P., Fishman, M., Dionne, R., & Mitchell, S. G. (2021). Drug and sexual HIV-risk behaviors among adolescents and young adults with opioid use disorder. Journal Substance Abuse Treatment, 130, 108477.
Ludwig, A., Monico, L. B., Lertch, E., Schwartz, R. P., Fishman, M., & Mitchell, S. G. (2021). Until there’s nothing left: Caregiver resource provision to youth with opioid use disorders. Substance Abuse, 42 (4), 990-997.
Mitchell, S. G., Monico, L. B., Gryczynski, J., Fishman, M. J., O’Grady, K. E., & Schwartz, R. P. (2021). Extended-release naltrexone for youth with opioid use disorder. Journal Substance Abuse Treatment, 130, 108407.
Monico, L. B., Ludwig, A., Lertch, E., Dionne, R., Fishman, M., Schwartz, R. P., & Mitchell, S. G. (2021). Opioid overdose experiences in a sample of US adolescents and young adults: A thematic analysis. Addiction, 116(4), 865-873.
Monico, L. B., Ludwig, A., Lertch, E., Schwartz, R. P., Fishman, M., & Mitchell, S. G. (2021). Post-residential treatment outpatient care preferences: Perspectives of youth with opioid use disorder. Journal of Substance Abuse Treatment, 108692.
Gordon MS, Mitchell SG, Blue TR, Vocci FJ, Fishman MJ, Murphy SM, CouvillionK, Maher K, Ryan D, Wenzel K, Danner ML, Jarvis DK (2020). A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. Journal of Substance Abuse Treatment 108241.
Monico LB, Ludwig A, Lertch E, Dionne R, Fishman M, Schwartz RP, Mitchell SG (2020). Opioid overdose experiences in a sample of US adolescents and young adults: A thematic analysis. Addiction.
Gordon MS, Vocci FJ, Taxman F, Fishman M, Sharma B, Blue TR, O’Grady KE (2019). A Randomized Controlled Trial of Buprenorphine for Probationers and Parolees: Bridging the Gap into Treatment Contemporary Clinical Trials 79:21-27. doi: 10.1016/j.cct.2019.02.009. Epub 2019 Feb 20. PMID: 30797042.
Gryczynski, J., Schwartz, R. P., Fishman, M., Nordeck, C.D., Grant, J., Nidich, S., Rothenberg, S., & O’Grady, K. E. (2018). Integration of Transcendental Meditation®(TM) into alcohol use disorder (AUD) treatment. Journal of Substance Abuse Treatment, 87, 23-30.
Nunes EV, Gordon MS, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hi MC, Boney TB, Wilson D, O’Brien CP (2018). Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone . Journal of Substance Abuse Treatment Available at: http://dx.doi.org/10.1016/j.jsat.2017.04.016.
Lee JD, Friedmann PD, Boney TY, Hoskinson RA Jr, McDonald R, Gordon MS, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O’Brien CP (2015). Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial Contemporary Clinical Trials 41:110-7.
Branson C, Clemmey P, Harrell P, Subramaniam G, Fishman M (2012). Polysubstance use and heroin relapse among adolescents following residential treatment Journal of Child and Adolescent Substance Abuse 21(3).
Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, Potter J, Fishman M, Bogenschutz M, Patkar A, Trivedi MH (2012). Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth Addictive Behaviors 37(9):1046-53.
Winstanley E, Steinwachs D, Stitzer M, Fishman M (2012). Adolescent substance abuse and mental health: Problem co-occurrence and access to services Journal of Child and Adolescent Substance Abuse 21(4): 310-22.
Fishman M J, Wu LT, and Woody G (2011). Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence American Journal of Psychiatry 168(7).
Subramaniam G, Warden D, Minhajuddin A, Fishman M, Stitzer M, Adinoff B, Trivedi M, Weiss R, Potter J, Poole S, Woody GE (2011). Predictors of abstinence: NIDA multi-site buprenorphine/naloxone treatment trial in opioid dependent youth Journal of the American Academy of Child and Adolescent Psychiatry 50(11):1120-8.
Fishman M (2010). Treatment planning, matching and placement for adolescent substance abuse. In: Kaminer Y, Winters K, eds. Clinical Manual of Adolescent Substance Abuse Treatment American Psychiatric Publishing
Fishman M (Chief Editor), Shulman J, Mee-Lee D, Kolodner G, Wilford B, eds (2010). ASAM patient placement criteria supplement on pharmacotherapy for alcohol use disorders Lippincott Williams and Wilkens
Fishman M, Winstanley E, Curran E, Garrett S, Subramaniam G (2010). Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case series and feasibility Addiction 105: 1669-1676.
Winstanley E, Bolon S, Fishman M (2010). Treatment outcomes for addictive disorders in Addictive Disorders in Medical Populations, Miller N and Gold M (eds) John Wiley & Sons, Ltd
Subramaniam G, Fishman M, Woody G (2009). Treatment of opioid-dependent adolescents and young adults with buprenorphine Current Psychiatry Reports 11:360–3.
Subramaniam G, Stitzer M, Woody G, Fishman M, Kolodner K (2009). Clinical characteristics of treatment seeking adolescents with opioid versus cannabis/alcohol use disorders Drug and Alcohol Dependence 99:141 49.
Subramaniam G, Stitzer M, Clemmey P, Kolodner K, Fishman M (2007). Baseline Depressive Symptoms Predict Poor Substance Use Outcome Following Adolescent Residential Treatment Journal of the American Academy of Child and Adolescent Psychiatry 46(8): 1062-9.
Mee-Lee D, Shulman GD, Fishman M, Gastfriend D, eds (2001). ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders, Second Edition-Revised (ASAM PPC-2R) American Society of Addiction Medicine, Inc